References
- Shtivelman E, Lifshitz B, Gale RP, et al. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985;315:550–554.
- Lugo TG, Pendergast AM, Muller AJ, et al. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247:1079–1082.
- Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1179–1190.
- Reiter A, Walz C, Watmore A, et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukaemia that fuses PCM1 to JAK2. Cancer Res 2005;65:2662–2667.
- Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukaemia. Science 1997;278:1309–1312.
- Krämer A, Reiter A, Kruth J, et al. JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukemia. Lancet Oncol 2007;8:658–660.
- Bornhäuser M, Mohr B, Oelschlaegel U, et al. Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia 2007;21:1824–1826.
- Hussein K, Bock O, Seegers A, et al. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2 V617F mutation. Blood 2007;109:4106–4107.
- Ribeiro de Mello Conchon M, Costa JL, Novaes MMY, et al. Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia. Int J Hematol 2008;88:243–245.
- Jallades L, Hayette S, Tigaud E, et al. Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis. Leuk Res 2008;32: 1608–1610.
- Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G> T is rare in acute leukemias but can be found in CMML, Philadelphia-chromosome-negative CML, and megakaryocytic leukemia. Blood 2005;106:3370–3373.
- Levine RL, Loriaux M, Huntly BJP, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005;106:3377–3379.
- Beham-Schmid C, Apfelbeck U, Sill H, et al. Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood 2002;99:381–383.
- Fenaux P, Beuscart R, Lai JL, et al. Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. J Clin Oncol 1988;6:1417–1424.
- Onida F, Kantarjian HM, Smith TL, et al. Prognostic factors and scoring systems in chronic myelomonoctic leukemia: a retrospective analysis of 213 patients. Blood 2002;99:840–849.